Effects of non-steroidal anti-inflammatory drugs on proliferation, differentiation and migration in equine mesenchymal stem cells

被引:46
作者
Mueller, Maike [2 ]
Raabe, Oksana [1 ]
Addicks, Klaus [2 ]
Wenisch, Sabine [1 ]
Arnhold, Stefan [1 ]
机构
[1] Univ Giessen, Dept Vet Anat, Giessen, Germany
[2] Univ Cologne, Dept Anat 1, Cologne, Germany
关键词
cell viability; differentiation; mesenchymal stem cell; migration; NSAID; tendinopathy; MARROW STROMAL CELLS; BONE-MARROW; IN-VITRO; UP-REGULATION; INHIBITION; TENDON; CELECOXIB; THERAPY; ASPIRIN; OSTEOARTHRITIS;
D O I
10.1042/CBI20090211
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
In equine medicine, stem cell therapies for orthopaedic diseases are routinely accompanied by application of NSAIDs (non-steroidal anti-inflammatory drugs). Thus, it has to be analysed how NSAIDs actually affect the growth and differentiation potential of MSCs (mesenchymal stem cells) in vitro in order to predict the influence of NSAIDs such as phenylbutazone, meloxicam, celecoxib and flunixin on MSCs after grafting in vivo. The effects of NSAIDs were evaluated regarding cell viability and proliferation. Additionally, the multilineage differentiation capacity and cell migration was analysed. NSAIDs at lower concentrations (0.1-1 mu M for celecoxib and meloxicam and 10-50 mu M for flunixin) exert a positive effect on cell proliferation and migration, while at higher concentrations (10-200 mu M for celecoxib and meloxicam and 100-1000 mu M for flunixin and phenylbutazone), there is rather a negative influence. While there is hardly any influence on the adipogenic as well as on the chondrogenic MSC differentiation, the osteogenic differentiation potential, as demonstrated with the von Kossa staining, is significantly disturbed. Thus, it can be concluded that the effects of NSAIDs on MSCs are largely dependent on the concentrations used. Additionally, for some differentiation lineages, also the choice of NSAID is critical.
引用
收藏
页码:235 / 248
页数:14
相关论文
共 45 条
[1]   Red Blood Cell Contamination of the Final Cell Product Impairs the Efficacy of Autologous Bone Marrow Mononuclear Cell Therapy [J].
Assmus, Birgit ;
Tonn, Torsten ;
Seeger, Florian H. ;
Yoon, Chang-Hwan ;
Leistner, David ;
Klotsche, Jens ;
Schaechinger, Volker ;
Seifried, Erhard ;
Zeiher, Andreas M. ;
Dimmeler, Stefanie .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (13) :1385-1394
[2]   Management of equine orthopedic pain [J].
Baller, LS ;
Hendrickson, DA .
VETERINARY CLINICS OF NORTH AMERICA-EQUINE PRACTICE, 2002, 18 (01) :117-+
[3]   Instrumentation and techniques for treating orthopedic infections in horses [J].
Baxter, GM .
VETERINARY CLINICS OF NORTH AMERICA-EQUINE PRACTICE, 1996, 12 (02) :303-+
[4]  
BERESFORD JN, 1992, J CELL SCI, V102, P341
[5]   COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: An in vitro analysis [J].
Beretta, C ;
Garavaglia, G ;
Cavalli, M .
PHARMACOLOGICAL RESEARCH, 2005, 52 (04) :302-306
[6]   Effects of aspirin, carprofen, deracoxib, and meloxicam on platelet function and systemic prostaglandin concentrations in healthy dogs [J].
Blois, Shauna L. ;
Allen, Dana G. ;
Wood, R. Darren ;
Conlon, Peter D. .
AMERICAN JOURNAL OF VETERINARY RESEARCH, 2010, 71 (03) :349-358
[7]   KETOROLAC - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC POTENTIAL [J].
BUCKLEY, MMT ;
BROGDEN, RN .
DRUGS, 1990, 39 (01) :86-109
[8]   Mesenchymal stem cells: building blocks for molecular medicine in the 21st century [J].
Caplan, AI ;
Bruder, SP .
TRENDS IN MOLECULAR MEDICINE, 2001, 7 (06) :259-264
[9]   NSAIDs and cancer prevention: Targets downstream of COX-2 [J].
Cha, Yong I. ;
DuBois, Raymond N. .
ANNUAL REVIEW OF MEDICINE, 2007, 58 :239-252
[10]   Concise review: Mesenchymal stem cells: Their phenotype, differentiation capacity, immunological features, and potential for homing [J].
Chamberlain, Giselle ;
Fox, James ;
Ashton, Brian ;
Middleton, Jim .
STEM CELLS, 2007, 25 (11) :2739-2749